共 426 条
[1]
Levine MN(2008)Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials Lancet 371 29-40
[2]
Pritchard KI(2005)Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5 J Clin Oncol 23 5166-5170
[3]
Bramwell VHC(2003)Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group Ann Oncol 14 833-842
[4]
Shepherd LE(2012)Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials Lancet 379 432-444
[5]
Tu D(2005)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687-1717
[6]
Paul N(2008)Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the women’s environment, cancer and radiation epidemiology study J Natl Cancer Inst 100 32-40
[7]
Martin M(1992)Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer Am J Epidemiol 136 925-936
[8]
Villar A(1995)Contralateral breast cancer: annual incidence and risk parameters J Clin Oncol 13 1578-1583
[9]
Sole-Calvo A(1988)Risk of contralateral breast cancer: associations with factors related to initial breast cancer Am J Epidemiol 128 309-323
[10]
Gonzalez R(2008)The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands Breast Cancer Res Treat 110 189-197